Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aptevo Therapeutics (APVO) EBITDA (2016 - 2025)

Aptevo Therapeutics (APVO) has disclosed EBITDA for 11 consecutive years, with -$6.0 million as the latest value for Q4 2025.

  • Quarterly EBITDA rose 6.05% to -$6.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$26.3 million through Dec 2025, down 6.95% year-over-year, with the annual reading at -$26.3 million for FY2025, 6.95% down from the prior year.
  • EBITDA hit -$6.0 million in Q4 2025 for Aptevo Therapeutics, up from -$7.6 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$4.0 million in Q4 2021 to a low of -$8.2 million in Q2 2023.
  • Historically, EBITDA has averaged -$6.5 million across 5 years, with a median of -$6.4 million in 2023.
  • Biggest five-year swings in EBITDA: skyrocketed 40.75% in 2021 and later plummeted 90.2% in 2022.
  • Year by year, EBITDA stood at -$4.0 million in 2021, then tumbled by 90.2% to -$7.7 million in 2022, then rose by 16.92% to -$6.4 million in 2023, then increased by 0.03% to -$6.4 million in 2024, then increased by 6.05% to -$6.0 million in 2025.
  • Business Quant data shows EBITDA for APVO at -$6.0 million in Q4 2025, -$7.6 million in Q3 2025, and -$6.2 million in Q2 2025.